26.06.2013Path breaking dental implant technology, Surflink®, receives awardYou are hereNewsPath breaking dental implant technology, Surflink®, receives award
SurfLink®, the patented implant surface treatment by NBMolecules®, produces a monolayer of permanently bound multi-phosphonate molecules on the surface of an implant. This novel phosphonate rich surface mimics one of the main constituents of bone, providing a significantly more favourable environment for implant integration with:
Up to 43% quicker bone healing around the implant
Up to 32% greater early fixation of the implant with the possibility to earlier use of the bone anchored prosthesis
Up to 39% greater long-term integration
Up to 21% increased long-term stability providing for longer prosthesis function
The significantly superior bone healing and greater implant integration are explained by the specific characteristics of the multi-phosphonated SurfLink® molecule:
Hydrophilic implant surface – water, proteins and cells from the blood are attracted to the implant surface, which enables quicker cell adhesion and colonisation, resulting in faster bone matrix formation and osseointegration.
Stability in a physiological environment - the SurfLink® molecule remains permanently bound to the implant surface between pH 1 and 9. In contrast, phosphates currently used on some implant surfaces are unstable and quickly dissolved at pH below 4, typical for inflammatory and bone remodelling situations. Unlike phosphates, phosphonated molecules such as SurfLink® are enzymatically stable.
Chemical Bonding - SurfLink® provides a chemical connection between bone and the implant surface, in addition to the mechanical interlocking due to the implant's roughened topography. This results in increased implant stability and fixation in comparison to an implant relying on mechanical interlocking only. Thus, after torque testing, a fracture within the bone was observed on SurfLink® treated implants, rather than at the bone-to-implant interface, as with control implants. This close attachment of bone to the implant surface is expected to contribute to maintaining functional and aesthetical bone fixation to the implant.
Osteoconductivity – starting from bone contact points, new bone matrix is quickly (within 2 weeks) formed along the SurfLink® treated implant surface, maturing to organised, mineralised bone within 8 weeks. The biomimetic characteristics of SurfLink® allows for a long-term optimal and true osseointegration.
In a clinical situation, these characteristics imply an enhanced clinical performance with possible earlier loading, greater preservation of marginal bone levels and longer implant survival, also in patients with compromised bone healing.
Over the past decades, advances in refining the surface properties of titanium dental implants have dramatically reduced implant failure rate. The use of biomimetic agents has substantially increased our understanding of what takes place at the bone-to-implant interface. As a result, biocompatibility of implants has improved. Osseointegration and subsequent implant stability have been furthered.
Biomimetic agent coatings, such as bioceramics (hydroxyapatite, and other calcium phosphate phases), have been placed on the implant market. Such surface coatings have presented some advantages, but have also produced certain integrity problems (dissolution, delamination, particlerelease) increasing implant failure rate. The SurfLink® Dental surface treatment, which permanently modifies the surface chemistry of implants, was developed to overcome the shortcomings of coatings.
The SurfLink® Surface treatment by NBMolecules® is applicable on metallic or ceramic implants, e.g. dental and orthopedic.
BioAlps World Visibitlity Package 201918.03.2019A yearly international programme for our affiliated companies to increase their visibility.
BioAlps World Visibitlity Package 2019A yearly international programme for our affiliated companies to increase their visibility.
Eclosion2 & cie SCPCInvestor, Public / Bank / Venture Capital FundsEclosion & cie SCPC is a life science investment fund focusing on translating cutting edge science into biotechnology companies developing transformational best-in-diseases therapeutics and platform technologies.
We are builders. Eclosion's approach is defined by its unique entrepreneurial mindset leading to a strong operational and investment commitment to start-up enterprises. Eclosion is driven by an experienced management team which brings together scientific, operational and financial expertise and a successful track record of company creation, value generation and development of new therapeutics that will transform human healthcare.
We focus on highly innovative science and early stage companies developing new approaches to address high unmet medical needs. Eclosion2 fund’s portfolio companies have developed first-in-class drugs with high potential value to patients in fields such as multiple sclerosis, fibrosis or oncology.
We are enablers. Eclosion private investment fund supports portfolio companies from seed to capital stage up to clinical proof of concept, making significant long term operational and financial commitments to companies that have the potential to change the way patients are treated.